Overview
- Hims & Hers will offer FDA‑approved Ozempic injections at 0.5 mg, 1 mg, and 2 mg and Wegovy in both pills and injections, including 1.7 mg and 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, and 25 mg tablets, on its U.S. telehealth platform later this month.
- The company is moving patients off compounded GLP‑1 products, retaining compounded options only when a provider determines they are clinically necessary.
- HIMS shares extended a multi‑day rally, up 10.27% Wednesday to $25.88 and 64% for the week by Wednesday’s close, with Thursday premarket gains reported at about 7%.
- Deutsche Bank, Citigroup, Bank of America, and Barclays raised targets or ratings following the agreement, with targets cited at $28, $24, $23, and $29, respectively.
- Bank of America linked its upgrade to Novo Nordisk’s withdrawal of prior litigation, while recent context includes a Q4 EPS beat of $0.08 and a $250 million share repurchase authorization.